Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) have been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $21.57.
RAPT has been the topic of several analyst reports. Wolfe Research restated a “peer perform” rating on shares of RAPT Therapeutics in a report on Tuesday, May 14th. Barclays cut shares of RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and cut their price target for the company from $13.00 to $4.00 in a report on Friday, May 10th. Guggenheim lowered shares of RAPT Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. Finally, HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research report on Tuesday, August 20th.
Get Our Latest Analysis on RAPT
Institutional Investors Weigh In On RAPT Therapeutics
RAPT Therapeutics Trading Down 1.7 %
RAPT opened at $2.02 on Friday. RAPT Therapeutics has a twelve month low of $1.95 and a twelve month high of $27.35. The firm has a market cap of $70.50 million, a price-to-earnings ratio of -0.66 and a beta of 0.36. The company has a fifty day simple moving average of $2.79 and a 200 day simple moving average of $5.49.
RAPT Therapeutics (NASDAQ:RAPT – Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.03. On average, analysts forecast that RAPT Therapeutics will post -2.73 earnings per share for the current fiscal year.
RAPT Therapeutics Company Profile
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See Also
- Five stocks we like better than RAPT Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Small Cap Stocks That Insiders Are Buying
- Market Cap Calculator: How to Calculate Market Cap
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Retail Stocks Investing, Explained
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.